REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc., trading under ticker TZAC, is the post-merger entity resulting from the de-SPAC transaction between Tenzing Acquisition Corp and Reviva Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing differentiated therapies for neuropsychiatric and metabolic disorders. Tenzing Acquisition Corp, sponsored by Tenzing Global Management, completed its IPO in 2019 targeting the healthcare and life sciences sector. The 10-K annual report filed May 4, 2020, under accession number 0001104659-20-055760, reflects the combined company's first full reporting cycle following the business combination. The merger positioned Reviva as a publicly traded pharmaceutical development company operating under the legacy SPAC ticker. Sign up for SpacDesk to access the full filing history, deal timeline, and sponsor data for TZAC and hundreds of other SPAC transactions.